Content Type: Article

  • Loosening Restrictions on Elective Surgery and Procedures – FAQs on Updated CMS, Administration and Association Guidance

    ARTICLE / CLIENT ALERT

    Loosening Restrictions on Elective Surgery and Procedures – FAQs on Updated CMS, Administration and Association Guidance

    April 2020

    Read time: 1 min

    Key takeaways
    Overview

     

    In depth
    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    More insights

  • CMS Provides Flexibility for Independent Freestanding Emergency Departments to Enroll in Medicare as Hospitals During the COVID-19 Pandemic

    ARTICLE / CLIENT ALERT

    CMS Provides Flexibility for Independent Freestanding Emergency Departments to Enroll in Medicare as Hospitals During the COVID-19 Pandemic

    April 23, 2020

    Read time: 11 min

    Key takeaways
    Overview

    On April 21, 2020, the Centers for Medicare & Medicaid Services (CMS) issued Quality, Safety & Oversight memorandum QSO-20-27-Hospital (QSO Memo), addressed to state survey agencies to provide guidance to independent freestanding emergency departments (Freestanding EDs) during the COVID-19 pandemic. CMS highlighted certain flexibility for Freestanding EDs, including the ability for a Freestanding EDs to temporarily enroll in Medicare as a hospital during the COVID-19 public health emergency. Providers should carefully consider how the facility can meet Medicare participation requirements for hospitals (taking into account all applicable Section 1135 waivers) and ensure conversion to a hospital is consistent with state licensure and state emergency preparedness and pandemic plans before moving forward with enrolling in Medicare as a hospital.

    In depth

    On April 21, 2020, CMS issued a QSO Memo, QSO-20-27-Hospital, to provide direction to state survey agencies regarding Freestanding EDs, including guidance for those Freestanding EDs that choose to temporarily enroll in Medicare as hospitals. CMS is providing flexibility to Freestanding EDs to expand capacity for inpatient and outpatient hospital services for patients in light of the COVID-19 pandemic. Specifically, Freestanding EDs may choose to: (1) affiliate with a Medicare-participating hospital under existing Section 1135 waivers; (2) enroll with state Medicaid agencies as a Medicaid clinic; or (3) temporarily enroll in Medicare as a hospital. CMS also highlighted these flexibilities for Freestanding EDs in a press release.

    Background

    On March 13, 2020, President Donald Trump declared a national emergency under the National Emergencies Act and made an emergency determination under the Stafford Act. This announcement followed the January 31, 2020, declaration of a public health emergency under the Public Health Service Act by the Secretary of the US Department of Health and Human Services (HHS). These actions opened the door for the authorization of waivers of certain Medicare, Medicaid and Children’s Health Insurance Program requirements as provided by Section 1135 of the Act (collectively, Section 1135 waivers). In the published Section 1135 waivers, CMS noted that hospitals are permitted to establish and operate as part of the hospital any location meeting the Medicare hospital conditions of participation (CoPs) not waived by the Section 1135 waivers. For additional guidance on Section 1135 waivers, please see our guidance here.

    CMS provided guidance on April 3, 2020, to state survey agencies regarding the process for ambulatory surgery centers (ASCs) to temporarily enroll in Medicare as hospitals in a Quality, Safety & Oversight memorandum, QSO-20-24-ASC. The most recent guidance permitting Freestanding EDs to enroll in Medicare is substantially similar to the guidance provided to ASCs. For additional details on ASC-to-hospital conversions, please see our analysis here.

    Licensed Independent Freestanding Emergency Departments

    Freestanding EDs are not recognized as certified Medicare providers and cannot bill Medicare or Medicaid for services. Medicare generally reimburses only EDs that bill under the National Provider Identifier of a Medicare-participating hospital. Therefore, although Freestanding EDs may provide care to Medicare beneficiaries, reimbursement for services provided in such facilities is generally limited to the reimbursement provided to physicians or other professionals for their services.

    Currently, only four states license Freestanding EDs: Colorado, Delaware, Rhode Island and Texas. All other states that license freestanding emergency departments require the ED to have an affiliation with a hospital.

    CMS has identified Freestanding EDs as a resource to expand capacity for inpatient and outpatient hospital services during the COVID-19 pandemic, and highlighted three options for these EDs in this regard:

    • The Freestanding ED may affiliate with an existing Medicare-participating hospital. This would result in the Freestanding ED being treated as a hospital outpatient department of the Medicare-participating hospital under existing flexibility provided under Section 1135 waivers.
    • The Freestanding ED may work with the state Medicaid agency to enroll as a Medicaid-certified clinic.
    • The Freestanding ED may temporarily enroll in Medicare as a hospital, as detailed below.

    Regardless of the option the Freestanding ED chooses to pursue, it should contact its state health department and state survey agency to determine the options under the state’s emergency and pandemic plan.

    Affiliation with an Existing Hospital

    Freestanding EDs are permitted to pursue an affiliation with a Medicare-participating hospital for the duration of the COVID-19 public health emergency, subject to certain limitations. The hospital and the Freestanding ED will need to work with the state where the facilities are located to ensure that the Freestanding ED will be permitted under state licensure requirements to operate as an outpatient department of the hospital. Freestanding EDs that choose to affiliate with a hospital will not be required to submit a Medicare enrollment application. Freestanding EDs that operate as an outpatient department of a hospital will not directly bill and collect for services; rather, the hospital will do so (as the Freestanding ED will function, for payment purposes, as part of the hospital). Accordingly, this option will entail the Freestanding ED entering into a contractual arrangement with the involved hospital on the financial and business terms of the arrangement.

    Freestanding EDs Enrolling as a Medicaid-Certified Clinic

    CMS has previously provided states with the ability to revise Medicaid state plan policies in light of the COVID-19 pandemic, including benefits covered by the state Medicaid program. States may submit an emergency State Plan Amendment to expand coverage to include Freestanding EDs as a facility eligible to provide services to Medicaid beneficiaries. A Freestanding ED may choose to enroll with the state Medicaid agency as a Medicaid-certified clinic. Freestanding EDs that elect this option will need to reach out to the state Medicaid agency to evaluate whether the state will cover services provided in Freestanding EDs and to enroll as a Medicaid-certified clinic. This option would permit Freestanding EDs to serve Medicaid beneficiaries and be reimbursed directly by the state Medicaid program for that care.

    Process and Limitations for Freestanding EDs Enrolling as Hospitals

    Freestanding EDs are temporarily permitted to enroll in Medicare as hospitals for the duration of the COVID-19 public health emergency, subject to certain limitations. The Freestanding ED must ensure that enrolling as a hospital is not inconsistent with the state’s emergency preparedness or pandemic plan.

    Any Freestanding ED that wishes to enroll as a hospital will need to:

    • Notify the Medicare Administrative Contractor (MAC) that serves the jurisdiction by calling the MAC’s provider enrollment hotline and following instructions provided in a Medicare provider enrollment FAQ
    • Submit a signed attestation statement to the MAC, as described below.

    Once the Freestanding ED has submitted a signed attestation statement to the MAC, the MAC will review and send the attestation to the applicable CMS Regional Office ( RO). The RO will review the Freestanding ED’s attestation and approve the attestation statement, assign a hospital CMS Certification Number (CCN) and send a final determination permitting the ASC’s enrollment (known as a tie-in notice) as a hospital to the MAC. The Freestanding ED’s date of enrollment will be retroactive to the date when the attestation was accepted by the MAC.

    An on-site survey is not required for approval, but the CMS RO may authorize a survey by the state survey agency at a later date to ensure quality and safety requirements are met. While survey activity has largely been suspended during the COVID-19 public health emergency, CMS, state agencies and accrediting organizations continue to conduct surveys related to infection control and patient safety. Once enrolled as a certified hospital, Freestanding EDs would be subject to the same enforcement actions as regularly certified hospitals.

    Compliance with Hospital Conditions of Participation

    Importantly, if a Freestanding ED chooses to enroll in Medicare as a hospital, the Freestanding ED must meet the hospital CoPs, to the extent such CoPs are not waived by Section 1135 waivers.

    The attestation statement required by the MAC as part of the temporary enrollment process highlights particular CoPs that must be met. A Freestanding ED that is temporarily converting to a hospital must ensure that the facility satisfies the following requirements before submitting the attestation to the MAC:

    • Nursing Services
      • Ensure adequate numbers of licensed registered nurses and other personnel are available to provide nursing care to all patients as needed
      • Provide 24-hour nursing services furnished or supervised by a registered nurse
      • Ensure drugs and pharmaceuticals are prepared and administered in accordance with Federal and State laws and according to the orders of the practitioner(s) responsible for the patient’s care
    • Pharmaceutical Services
      • Provide pharmaceutical services that meet the needs of the patients
      • Have a pharmacy directed by a registered pharmacist or a drug storage area under competent supervision
      • Provide a full-time, part-time or consultant pharmacist who is responsible for all activities of the pharmacy services
      • Provide an adequate number of personnel to ensure high quality pharmaceutical services, including emergency services
      • Ensure drugs listed in Schedules II, III, IV and V of the Comprehensive Drug Abuse and Prevention and Control Act of 1970 are kept locked within a secure area
    • Infection Control
      • Appoint a qualified individual as the Infection Preventionist/Infection Control Professional
      • Employ methods for preventing and controlling the transmission of infections within the hospital and between other providers
      • Create an Infection Control Surveillance plan to control Healthcare Acquired Infections
      • Establish a hospital-wide antibiotic stewardship program in accordance with national standards
    • Respiratory Services
      • Ensure that the facility has a director of respiratory care services who is a doctor of medicine or osteopathy who is available on a full or part-time basis to supervise and administer respiratory services
      • Ensure an adequate number of qualified respiratory therapists and technicians
      • Ensure all respiratory services are delivered in accordance with medical staff directives

    Any other CoPs that are not waived by Section 1135 waivers must also be met before the facility converts to a hospital.

    In addition, a Freestanding ED that temporarily enrolls as a hospital will be required to provide a Medicare Outpatient Observation Notice (MOON) (CMS-10611) to all Medicare beneficiaries, including Medicare Advantage enrollees, informing beneficiaries that they are outpatients receiving observation services and are not inpatients of the hospital.

    Key Takeaways

    Despite the flexibility provided by CMS to expand options available to Freestanding ED to participate in Medicare and Medicaid, the Freestanding ED will need to ensure that any option it chooses to pursue is not inconsistent with the state emergency and pandemic plan. A Freestanding ED should contact its state health department and survey agency to determine the options under the particular state’s emergency and pandemic plan, and to coordinate on any plans to change its enrollment status.

    While Freestanding EDs may be eager to take advantage of the flexibility provided by CMS to enroll in Medicare as a hospital and take advantage of higher reimbursement, such Freestanding EDs should be aware that complying with hospital CoPs is a fundamental requirement of participating in Medicare as a hospital. The attestation that must be submitted by the Freestanding ED to convert into a hospital requires the facility to attest that it will meet all applicable federal participation requirements. While many CoPs have been waived by CMS under Section 1135, the ability to meet the non-waived CoPs may be a challenge for Freestanding EDs. As such, submission of the attestation confirming that the facility can and will meet all hospital CoPs could later expose the Freestanding ED to liability if it does not achieve and maintain compliance during the period it is enrolled as a hospital.

    Similarly, before deciding to move forward with either a conversion or an affiliation with a Medicare-participating hospital, Freestanding EDs will need to carefully consider the state law implications. As an initial matter, the Freestanding ED must ensure that enrolling as a hospital or affiliating with an existing hospital is not inconsistent with the state’s emergency preparedness or pandemic plan. The Freestanding ED must also ensure that the state will allow for the facility to be licensed as a hospital or otherwise recognize the unique operating circumstances created by the COVID-19 pandemic and supports the ED’s proposed conversion or affiliation. Freestanding EDs will also want to ensure that there is a pathway to revert to their existing state licensure (as applicable) after the COVID-19 public health emergency ends.

    Finally, while Medicare will recognize and reimburse a converted Freestanding ED for hospital services, it is unclear at this point whether commercial payors will similarly recognize and reimburse such Freestanding EDs for services provided at hospital reimbursement rates after the facility converts from an ED to a hospital.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Caroline Reignley

    Partner

    Washington, DC

    More insights

  • ONC and CMS Delay Enforcement Dates for Certain Provisions of the 21st Century Cures and Interoperability Final Rules, and OIG Announces Proposed Rule to Implement Information Blocking Enforcement Authority

    ONC and CMS Delay Enforcement Dates for Certain Provisions of the 21st Century Cures and Interoperability Final Rules, and OIG Announces Proposed Rule to Implement Information Blocking Enforcement Authority

    CLIENT ALERT / INFORMATION BLOCKING

    ONC and CMS Delay Enforcement Dates for Certain Provisions of the 21st Century Cures and Interoperability Final Rules, and OIG Announces Proposed Rule to Implement Information Blocking Enforcement Authority

    April 23, 2020

    Read time: 9 min

    Key takeaways
    Overview

    On April 21, 2020, the US Department of Health and Human Services (HHS) Office of the National Coordinator for Health Information Technology (ONC) and Centers for Medicare & Medicaid Services (CMS) announced that they will exercise discretion to delay enforcement of certain provisions of their final information blocking and interoperability rules beyond the compliance dates established by these rules. In addition, the HHS Office of Inspector General (OIG) announced a proposed rule amending its civil monetary penalty (CMP) regulations to incorporate new CMP authorities for information blocking.

    In depth

    The Office of the National Coordinator for Health Information Technology (ONC) and the Centers for Medicare & Medicaid Services (CMS) first displayed the contents of their information blocking and interoperability final rules on March 9, 2020. Those rules contained various compliance dates for new requirements that were tied to the publication date of the final rules in the Federal Register. After initially delaying the compliance dates by withholding the final rules from publication in the wake of the Coronavirus (COVID-19) public health emergency, the agencies have now announced that the final rules will be published in the Federal Register on May 1, 2020. ONC and CMS will then exercise discretion to delay enforcement of certain provisions beyond the compliance dates published in the final rules in recognition of the health care industry’s current focus on the ongoing COVID-19 public health emergency.

    Importantly, the enforcement delays announced by ONC and CMS do not affect the substantive requirements of the final rules. For more information on the substance of the final rules, please see our Special Alert and our other On The Subjects here and here.

    In this On The Subject, we discuss the new compliance dates of the ONC and CMS final rule requirements and review OIG’s proposed amendments to the CMP rules.

    ONC Final Rule

    ONC announced that it will exercise its discretion and not enforce the new certification requirements of its final rule until three months after each compliance date or timeframe identified in the ONC final rule. Along with the announcement, ONC published a helpful table outlining the compliance timeframes for each of these provisions and the effect of the enforcement delay. ONC did not extend the compliance date for the information blocking provisions of its final rule, but as discussed below OIG’s rulemaking will determine the timing of enforcement activity. Below, we provide the key compliance dates based on the enforcement delays announced by ONC:

    • ONC will begin enforcing two of the new conditions of certification (CoCs) on September 30, 2020 (three months from the June 30, 2020, compliance date in the final rule):
      • Under the final rule, certified health IT developers may only prohibit or restrict communications by its customers about certified health IT under limited exceptions intended to allow the developer to reasonably protect its intellectual property. While developers must adhere to this CoC beginning September 30, 2020, they will have until March 31, 2021, to provide the required notice for the 2020 calendar year to customers stating that non-compliant confidentiality provisions or other restrictions or limitations on communications in existing contracts between the developer and the customer are invalid.
      • Certified health IT developers must ensure that their certified health IT conforms to the full scope of the certification criteria applicable to the developer, and that the developer has not taken any action to interfere with a user’s ability to access or use certified capabilities.
    • ONC will enforce the following CoCs on February 1, 2021 (three months after the November 1, 2021, compliance date for these provisions in the final rule):
      • Certified health IT developers may not take any action that constitutes information blocking under the final rule.
      • Certified application programming interface (API) developers must meet the CoCs relating to API transparency (publicly publishing business and technical documentation), charge only permissible API fees and offer APIs on open and pro-competitive terms.
    • ONC will enforce the following CoCs on August 1, 2022 (three months after the May 1, 2022, compliance date for these provisions under the final rule):
      • Certified health IT developers with currently certified APIs must meet the new API certification criteria, which includes implementation of the Fast Healthcare Interoperability Resources (FHIR) standard.
      • Certified health IT developers will by this date need to have updated their products to comply with the United States Core Data for Interoperability (USCDI) criteria.
    • Certified health IT developers must submit initial plans for real-world testing to their certification bodies so that their certification bodies may evaluate the plan’s completeness and submit the plan to the ONC’s Certified Health IT Product List (CHPL) by March 15, 2021 (three months from the December 15, 2020 compliance date in the final rule). Certification bodies will be required to post certified health IT developers’ real-world testing results to the CHPL by June 15, 2022 (three months from the March 15, 2022, compliance date in the final rule).
    • Certified health IT developers will be required to submit their initial attestation that they adhered to the CoCs effective during the period of September 30, 2020 – March 31, 2021 by July 30, 2021.
    • Developers must meet the new electronic health information (EHI) export certification criterion by August 1, 2023 (three months after the May 1, 2023, compliance date under the final rule).

    CMS Interoperability Final Rule

    The CMS final rule requires Medicare Advantage plans, Medicaid state agencies, Medicaid managed care plans, CHIP agencies, CHIP managed care entities, and issuers of qualified health plans on federally-facilitated exchanges (Covered Plans and Agencies) to implement APIs that allow patient information to be shared more readily with third-party applications selected by patients. The new API requirement for Covered Plans and Agencies was scheduled to go into effect on January 1, 2021. However, CMS announced it will exercise enforcement discretion for the API requirement for a period of six months until July 1, 2021.

    Notably, however, CMS announced that all other policies in the final rule concerning Covered Plans and Agencies will be implemented and enforced on schedule. Covered Plans and Agencies will therefore still be expected by January 1, 2022, to have the ability to, in response to a patient’s request, forward patient information electronically to other payors designated by a requesting patient for up to five years after the patient has disenrolled from the plan.

    The CMS final rule also requires Medicare hospitals that have adopted electronic health record systems to, as a condition of participation (CoP) in the Medicare program, electronically report patient admissions, discharges, and transfers to patients’ primary care practitioners or other practitioners primarily responsible for the patient’s care. Originally, the final rule made the new CoP effective for hospitals six months following publication of the final rule. However, CMS announced that it has changed the text of the final rule to state that the CoP will now be effective May 1, 2021 (12 months after the final rule’s publication).

    OIG Proposed CMP Rule Amendments

    On April 21, 2020, OIG released a proposed rule amending its civil monetary penalty (CMP) regulations. Among other things, OIG’s proposed rule would incorporate statutory changes, including those related to new CMP authorities for information blocking, into OIG’s existing CMP regulations. OIG states that it intends for the proposed information blocking enforcement regulations to “improve coordination within the health care system and patients’ access to their health care data.”

    Enforcement Timing

    Consistent with ONC’s discussion in the preamble to its final rule, OIG states that it will not begin CMP enforcement before ONC’s information blocking compliance date (November 1, 2020). OIG also proposes that, in any event, it will not begin enforcement until at least 60 days after OIG issues a final rule. Conduct occurring between ONC’s compliance date and OIG’s effective date—if ONC’s compliance date occurs first—will not be subject to CMPs. Of note though, OIG is considering an alternative proposal that would establish an effective date on a date certain. OIG identifies October 1, 2020, as a date under consideration, but is also considering earlier or later dates. OIG is seeking comment on when it should begin enforcement and how various considerations, including the ongoing COVID-19 pandemic, should affect information blocking enforcement timing.

    OIG Enforcement Priorities

    OIG states that its proposed rule does not include new information blocking requirements, but instead seeks to formally incorporate ONC’s information blocking regulations as the basis for OIG imposing information blocking CMPs. OIG does, however, provide examples of how it plans to determine whether an actor’s practice resulted in one or many information blocking violations, which is relevant to determining the amount of potential penalties and is an area where the regulated industry is likely to have a significant interest in providing feedback.

    Like other OIG authorities that include an intent element, OIG acknowledges that each information blocking allegation will require a facts and circumstances analysis, which OIG will conduct in coordination with ONC and the HHS Office for Civil Rights. In terms of enforcement priorities, OIG states that it will focus on investigating conduct that (1) involves patient harm; (2) impacts providers’ ability to deliver patient care; (3) continues for a long time; (4) results in financial loss for Medicare, Medicaid, and other federal health care programs as well as other government and private entities; and (5) involves an actor engaging in the conduct with “actual knowledge.”

    The last focus area is noteworthy because the 21st Century Cures Act provides for CMPs to be issued in situations in which health IT developers, health information exchanges and health information networks “know” or “should know” that their practices are likely to interfere with the access, exchange or use of EHI. OIG seems to be saying that it plans to focus on a subset of conduct that it could otherwise pursue for CMPs. That said, OIG goes out of its way in the proposed rule to note that the stated priorities in the preamble guidance will not legally restrict OIG’s discretion to choose the complaints it investigates.

    Public Comment

    OIG seeks public comment on its proposed rule. Interested stakeholders will have 60 days from the date of the proposed rule’s publication in the Federal Register to submit comments, though OIG stated that it will monitor requests for an extended comment period due to the COVID-19 public health emergency. The proposed rule is scheduled for publication on April 24, 2020.

    Please do not hesitate to contact your regular McDermott lawyer or any of the authors of this On The Subject if you have questions or need assistance with your compliance obligations under the ONC/CMS final rules or if you have questions or wish to comment on the OIG proposed rule.

    Authors

    James A. Cannatti III

    Partner

    Washington, DC

    Daniel F. Gottlieb

    Partner

    Chicago

    Karen S. Sealander

    Counsel

    Washington, DC

    More insights

  • Coalition Committee: Increase of Short-time Work Allowances

    Coalition Committee: Increase of Short-time Work Allowances

    ARTICLE / CLIENT ALERT

    Coalition Committee: Increase of Short-time Work Allowances

    April 23, 2020

    Read time: 3 min

    Key takeaways
    Overview

    On the evening of April 23, 2020, the coalition committee agreed on further measures to soften social and economic hardship resulting from the ongoing Coronavirus pandemic. Among other measures, short-time work allowances is to be increased.

    Short-time work allowances is to be increased according to a time scale from 60% to up to 80% (67% to 87% for households with children).

    Precondition for the increase should be that the respective employees in short-term work are affected by at least 50% loss of working hours.

    From the fourth month of short-term work, the short-term work allowances is then to be further increased to 70% or rather 77% of the lost net salary and from the seventh month onwards to 80% or rather 87%. Currently, the maximum period for which short-term work allowances can be drawn is 12 months.

    The new regulation will initially be limited until December 31, 2020.

    Employers should take into account the increases in topping-up provisions.

    The increase may lead to uncertainties in dealing with contractual or collective topping up provisions. If the employer has promised a percentage increase in short-term work allowances, it is questionable whether this should then also apply to the increased short-term work allowances. If, on the other hand, the regulations provide for an increase in the difference in pay, no application problems should arise: In this instance, the topping up provision may not apply. If agreements on short-term work are currently being negotiated with the works council or employees, this aspect should, however, be taken into account and it should be made clear that the employer’s obligation to top up to a certain percentage of the difference in pay only extends as far as the state does not compensate for this with the short-term work allowances.

    Implementation

    The resolutions of the coalition committee must be passed by the German Federal Parliament (Bundestag) for the most part as amendments to the law. As an increase in the short-term work allowances plans is only to take place from the fourth month onwards, there is no particular hurry for the short-term work cases currently ordered due to the Coronavirus, as companies will only be in the second month of short-term work at most and the new regulation would then only become relevant on June 1, 2020. If the time limit is implemented as planned, companies and employees could then benefit from a total of no more than four months of the maximum short-term work allowances until the end of the year.

    In depth
    Authors

    Dr. Thomas Gennert

    Partner

    Düsseldorf

    Volker Teigelkötter

    Partner

    Düsseldorf

    More insights

  • Decisions Applying the § 315(b) Time Bar When Instituting IPR Proceedings Nonappealable

    Decisions Applying the § 315(b) Time Bar When Instituting IPR Proceedings Nonappealable

    ARTICLE / CLIENT ALERT

    Decisions Applying the § 315(b) Time Bar When Instituting IPR Proceedings Nonappealable

    April 22, 2020

    Read time: 5 min

    Key takeaways
    Overview

    Addressing the scope of review of the PTAB’s application of the one-year time bar of 35 U.S.C. § 315(b) in deciding whether to institute an IPR proceeding, the US Supreme Court held that the PTAB’s application of the time bar is nonappealable.

    In depth

    Addressing the scope of review of the Patent and Trademark Office (PTO) Patent Trial and Appeal Board’s (PTAB) application of the one-year time bar of 35 U.S.C. §315(b) in deciding whether to institute an inter partes review (IPR) proceeding, the US Supreme Court held that application of the time bar by the PTAB is nonappealable. Thryv, Inc. v. Click-to-Call Techs., LP, Case No. 18-916 (Apr. 20, 2019) (Ginsburg, Justice) (Gorsuch, Justice, joined in part by Sotomayor, Justice, dissenting). The Court explained an appeal based on the PTAB’s application of the time bar for filing an IPR petition is prohibited under 35 U.S.C. § 314(d), which states that the PTAB’s decision on institution “shall be final and nonappealable.”

    Click-to-Call owns a patent related to technology for anonymous telephone calls. In 2001, the patent was asserted against a predecessor in interest to Thryv, but the case ended in a voluntary dismissal. In 2013, Thryv filed an IPR petition (under its former name of Ingenio) challenging certain claims of the patent. Click-to-Call argued that because of the 2001 lawsuit, Thryv’s privy had been served with a complaint more than one year earlier and the petition was time barred under § 315(b). The PTAB disagreed and instituted an IPR proceeding. After the PTAB’s final decision invalidated the challenged claims, Click-to-Call appealed, claiming that the PTAB exceeded its authority to issue the final decision because if it had properly applied the time bar of § 315(b), the IPR proceeding should never have been instituted.

    The Federal Circuit dismissed the appeal for lack of jurisdiction on the basis that § 314(d) precludes judicial review of the PTAB’s application of § 315(b). The Supreme Court, soon after its intervening decision in Cuozzo Speed Technologies, LLC v. Lee (IP Update, Vol. 19, No. 7), granted certiorari, vacated the judgment and remanded. The Federal Circuit then dismissed the appeal on the same basis as it had previously. However, in light of its en banc decision in Wi-Fi One, LLC v. Broadcom Corp. (IP Update, Vol. 19, No. 10) holding that “the time-bar determinations under § 315(b) are appealable,” the Federal Circuit granted panel rehearing and held that the PTO erred by instituting the IPR because the petition was time barred due to the service of the complaint in the 2001 lawsuit. The Supreme Court granted certiorari to resolve whether the PTAB’s application of § 315(b) is reviewable (IP Update, Vol. 21, No. 5).

    The Court largely reiterated its reasoning in Cuozzo and held that because the § 315(b) time bar is “closely tied to the application and interpretation of statutes related to” the institution determination, a party may not appeal the PTAB’s application of the one-year time bar of § 315(b). Click-to-Call argued that § 314(d)’s prohibition on appealing institution decisions should be limited to the PTAB’s determination “under this section,” i.e., only as to the requirements listed in § 314. The Court rejected that argument, explaining that Cuozzo, a case that addressed the nonappealability of PTAB’s decisions dealing with the requirement of “particularity” in connection with petitions under § 312(a)(3), foreclosed that argument. The Court noted that its understanding of the statute aligned with the AIA’s goal of weeding out “bad patents,” because it focuses appeals on the substantive issues of patentability. Allowing appeals because of a defect in the institution decision would allow a patent to survive, even though the PTAB already determined it to be unpatentable.

    Justice Ginsburg, noting the presumption favoring judicial review, allowed that the Supreme Court in Cuozzo did “reserve judgment” on whether § 314(d) would bar all appeals, such as those “that implicate constitutional questions.” However, the Court explained that since the time bar question is closely related to the institution decision, the time bar issue did not meet that criteria. The Court observed that § 315(b) “governs institution and nothing more,” and therefore, any appeal is merely “a contention that the agency should have refused ‘to institute an inter partes review.’”

    The Court also distinguished its decision in SAS Institute, which held that the PTAB’s application of § 318(a) was appealable. SAS Institute addressed the manner in which the agency’s review proceeds once instituted, not whether the PTAB should have instituted a proceeding (IP Update, Vol. 21, No. 5).

    In a lengthy narrative dissent, Justice Gorsuch would have limited § 314(d)’s prohibition on appeal to applications of the subsections “under this section” of § 314, as explicitly stated in the text of the statute, especially given the strong presumption in favor of judicial review. The dissent claimed that under the majority’s interpretation, “this section” becomes superfluous, even though that same phrase provides substantive importance in numerous other sections of the AIA. The dissent also suggests that Oil States, which held that IPR proceedings were not an unconstitutional taking of property, was wrongly decided.

    Authors

    Paul Devinsky

    Senior Counsel

    Washington, DC

    More insights

  • DOL and IRS Expand Access to Multiple Employer Plans and Propose to Eliminate the “One Bad Apple” Rule

    ARTICLE

    DOL and IRS Expand Access to Multiple Employer Plans and Propose to Eliminate the “One Bad Apple” Rule

    April 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Inconsistent HIPAA and CCPA De-Identification Standards Create Compliance Challenges

    ARTICLE

    Inconsistent HIPAA and CCPA De-Identification Standards Create Compliance Challenges

    April/May 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Daniel F. Gottlieb

    Partner

    Chicago

    Mark E. Schreiber

    Counsel

    Boston

    More insights

  • California Bill Proposes CCPA Exceptions for HIPAA De-Identified Information, Other Health Data

    California Bill Proposes CCPA Exceptions for HIPAA De-Identified Information, Other Health Data

    ARTICLE

    California Bill Proposes CCPA Exceptions for HIPAA De-Identified Information, Other Health Data

    April 2020

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Daniel F. Gottlieb

    Partner

    Chicago

    More insights

  • Overnight LIBOR and SOFR Performance During the COVID-19 Crisis

    Overnight LIBOR and SOFR Performance During the COVID-19 Crisis

    ARTICLE / CLIENT ALERT

    Overnight LIBOR and SOFR Performance During the COVID-19 Crisis

    April 22, 2020

    Read time: 4 min

    Key takeaways
    Overview

    As financial market participants are aware, the London Interbank Offered Rate (“LIBOR”) is not likely to continue after Dec. 31, 2021, for the currencies and maturities for which it is currently calculated and reported. Even if it does continue after that date, it is likely that it will not be representative of the same rate because in July 2017, the United Kingdom’s Financial Conduct Authority (“FCA”) announced its intention not to sustain LIBOR after the end of 2021.

    For market participants expecting or supporting a delay in the implementation of this change, in particular in light of the effects of the global pandemic resulting from COVID-19, as of the date of this writing there has been no statement to that effect from the FCA or from LIBOR’s administrator. Therefore, as of this date, it is still expected that the panel banks which submit information for the calculation of LIBOR interest rates will not be compelled to do so after 2021. Market participants should continue preparing for the discontinuation of LIBOR to occur by the end of 2021, unless and until the FCA indicates otherwise.

    In the United States, the Alternative Reference Rates Committee (“ARRC”) of the Federal Reserve has proposed the Secured Overnight Financing Rate (“SOFR”) as a replacement for U.S. dollar LIBOR as a reference rate in financial contracts. For contracts transitioning from LIBOR to SOFR, the ARRC proposes that a reference rate modifier be used to align the SOFR based replacement reference rate more closely with the LIBOR based reference rate. The New York Federal Reserve (“NY Fed”) has been publishing overnight SOFR rates since April 2018. In March 2020, the NY Fed began publishing compounded averages of SOFR over rolling 30-day, 90-day and 180-day periods (“SOFR Averages”).

    The table attached includes a comparison of overnight U.S. dollar LIBOR, an unsecured rate, and SOFR, a secured rate, from the beginning of March 2020 to April 17, 2020, which includes the period in late March prior to legislative and other regulatory efforts to address the financial effects of the COVID-19 health crisis. Although LIBOR is also published for one-month, three-month and six-month periods, and SOFR Averages are now published for rolling 30-day, 90-day and 180-day periods, a side-by-side comparison is an “apples-to-oranges” comparison because the LIBOR rates are forward-looking rates, while the SOFR Averages look back over the relevant time periods.

    It is not surprising that during this period, and in particular from March 16 to March 27, overnight SOFR tightened in comparison to overnight LIBOR. The difference in how they performed underscores the need for market participants to be prepared in advance for the transition from LIBOR, in particular if global events in late 2021 or early 2022 (like global events during the first quarter of 2020) do not accommodate a timely and smooth transition. If there is a lesson to be learned from Q1 2020, it is that the time to prepare for significant and material changes, like the LIBOR transition, is sooner rather than later.

    View the table.

    Authored by Phillip J. Azzollini, Taleah E. Jennings, Douglas I. Koff, Craig Stein and Atul Joshi


    This is a fast-moving topic and the information contained in this Alert is current as of the date it was published.

    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Phillip J. Azzollini

    Partner

    New York – 919 Third Avenue

    Taleah E. Baez

    Senior Partner

    New York – 919 Third Avenue

    Douglas I. Koff

    Partner

    New York – 919 Third Avenue

    Craig Stein

    Partner

    New York – 919 Third Avenue

    More insights

  • CMS Enhances COVID-19 Reporting and Surveillance Obligations for Long Term Care Facilities

    ARTICLE / CLIENT ALERT

    CMS Enhances COVID-19 Reporting and Surveillance Obligations for Long Term Care Facilities

    April 21, 2020

    Read time: 5 min

    Key takeaways
    Overview

    The Centers for Medicare and Medicaid Services (CMS) issued a Quality, Safety and Oversight Group (QSO) memorandum (QSO-20-26-NH) informing long term care facilities, including nursing homes, about new reporting and surveillance requirements issued as result of the Coronavirus (COVID-19) pandemic. CMS considers these efforts to be crucial elements in the federal plan to incrementally reopen the economy and will promulgate rules to implement these requirements imminently, which are expected soon.

    In depth

    On April 19, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a Quality, Safety and Oversight Group (QSO) memorandum (QSO-20-26-NH) informing long term care facilities, including nursing homes, about certain upcoming regulatory changes as a result of COVID-19, the disease caused by the 2019 novel coronavirus. Specifically, long term care facilities were notified about certain changes regarding (i) reporting of COVID-19 cases to the Centers for Disease Control and Prevention (CDC), (ii) reporting cases of COVID-19 to facility residents and family members and (iii) requiring long term care facilities to cooperate with CDC regarding surveillance efforts. CMS considers these reporting and surveillance efforts as crucial elements in President Trump’s Opening Up America plans, which seek in part to incrementally scale back on business and social restrictions as testing increases and infection and mortality rates decrease.

    Reporting Cases to the CDC

    Existing long term care facility Medicare and Medicaid requirements (42 CFR 483.80(a)(2)) and guidance from the CDC obligate long term care facilities to notify state and local health departments about reportable diseases, including suspected or confirmed COVID-19 among residents, any instances of residents with severe respiratory infection resulting in hospitalization or death, or three or more residents or staff experiencing new respiratory symptoms within 72 hours of each other.

    However, to date, federal agencies had not been collecting and analyzing the data contained in these reports. Whereas long term care facilities had the option of sharing reporting data with CDC in the past, new rules will require reporting to support CDC’s COVID-19 surveillance efforts. CMS and CDC plan to provide instructions to long term care facilities regarding standard formatting and frequency with which to report COVID-19 data to the CDC National Healthcare Safety Network. Details regarding these reports are anticipated as part of rulemaking efforts outlined in QSO 20-26-NH.

    Reporting Cases to Residents and Family Members

    CMS has also announced intentions to promulgate rules requiring long term care facilities to notify residents and their representatives about facility-level conditions. CMS anticipates that these rules will require long term care facilities to share information with residents and their representatives in at least four scenarios:

    • Within 12 hours of the occurrence of a single confirmed infection of COVID-19
    • When three or more residents and/or staff experience new respiratory symptoms within 72 hours of each other
    • Weekly updates to residents and representatives, regarding conditions in the facility, in addition to the more frequent reports when new infections or pockets of respiratory symptoms arise
    • Frequent reports regarding the facility’s endeavors to mitigate, prevent or reduce the risk of COVID-19 transmission, including whether normal operations at the facility will be altered

    While CMS has not provided a timeline for rulemaking or identified whether stakeholders will be provided with an opportunity to comment on the proposed rules through the typical notice and comment processes, it has forecasted that a facility’s non-adherence with COVID-19 reporting requirements could result in an enforcement action.

    Cooperation with Public Health Surveillance

    QSO 20-26-NH further reminds long term care facilities of the requirement to cooperate with public health entities (42 CFR 483.10(f)(4)(i)(A) and (B)). To that end, long term care facilities must provide state public health authorities or a representative of the Secretary of Health and Human Services with access to residents upon request. CMS anticipates that access may be necessary for on-site surveillance activities, testing of healthcare personnel and residents, or other related activities as permitted by applicable law.

    While state and local health department reporting requirements are currently in effect, the new requirements to report to the CDC, patients and their representatives will be effective as set forth in the upcoming rules. We will continue to monitor CMS’ rulemaking efforts regarding long term care facility reporting and surveillance obligations and will update this On the Subject accordingly.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Monica Wallace

    Partner

    Chicago

    More insights